Bile Acids and Their Receptors / edited by Stefano Fiorucci, Eleonora Distrutti
Preface -- Part 1. Bile acids as signaling molecules and their receptors -- 1. A short history of bile acid pharmacology -- 2. Bile acids activated receptors: a review of GPBAR1 (TGR5) and other G-protein-coupled receptors -- 3. Bile acid activated receptors: a review of FXR and other Nuclear receptors -- 4. The intestinal enterokine fibroblast growth factor 15/19 in bile acid metabolism -- 5. Signaling from intestine to the host. How bile acids regulate intestinal and liver immunity -- Part 2. General pharmacology of bile acid activated receptors and their ligands -- 6. Modeling of bile acid activated receptors as a tool for pharmacological development -- 7. Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists and antagonists -- 8. Non steroidal FXR ligands: current status and clinical applications -- 9. Intestinal selective FXR agonists and their potential in treating liver and metabolic diseases -- Part 3. Bile acids and their derivatives as drugs -- 10. UDCA, Nor-UDCA and T-UDCA: a review of their mechanisms of action and clinical applications -- 11. Chenodeoxycholic acid: an update on its therapeutic appplications and safety profile -- 12. Obeticholic acid: a review of its mechanisms of action and clinical applications -- Part 4. Bile acid activated receptors as therapeutic targets -- 13. Targeting FXR in cholestasis -- 14. FXR agonists for the treatment of NASH and other metabolic disorders -- 15. Targeting bile acids activated receptors in bariatric surgery.
This book focusses on the latest results related to the field of bile acids as signaling molecules and describes how these receptors have become a major pharmacological target. It covers all major areas of research in this field, from genetics, chemistry, in silico modeling, molecular biology to clinical applications, offering a cross-country view of the functional role of bile acids as signaling molecules, virtually acting on all major areas of metabolism. While FXR and GPBAR1 are essential bile acid sensors that integrate the de novo bile acid synthesis with intestinal microbiota and liver metabolism, in a broader sense, BARs play a pathogenic role in the development of common human alignments including liver, intestinal and metabolic disorders, such as steatosis (NAFLD) and steato-hepatitis (NASH), diabetes, obesity and atherosclerosis.
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
Cham: Springer ; 2019 |
| Ausgabe: |
1st ed. 2019 |
| Weitere Ausgaben: |
Erscheint auch als Druck-Ausgabe: Handbook of experimental pharmacology ; volume 256: Bile acids and their receptors |
|---|
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fiorucci, Stefano [HerausgeberIn] |
|---|
| Links: |
doi.org [lizenzpflichtig] |
|---|
| ISBN: |
|---|
| RVK: |
|---|
| Umfang: |
1 Online-Ressource (X, 378 p. 57 illus., 37 illus. in color) |
|---|
| doi: |
10.1007/978-3-030-22005-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1678685437 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1678685437 | ||
| 003 | DE-627 | ||
| 005 | 20230426135311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191010s2019 gw |||||o 00| ||eng c | ||
| 020 | |a 9783030220051 |9 978-3-030-22005-1 | ||
| 024 | 7 | |a 10.1007/978-3-030-22005-1 |2 doi | |
| 035 | |a (DE-627)1678685437 | ||
| 035 | |a (DE-599)KEP047001283 | ||
| 035 | |a (DE-He213)978-3-030-22005-1 | ||
| 035 | |a (EBP)047001283 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XA-DE | ||
| 050 | 0 | |a RM1-950 | |
| 060 | 0 | |a WI 703 | |
| 072 | 7 | |a MKG |2 thema | |
| 072 | 7 | |a MMG |2 bicssc | |
| 072 | 7 | |a MED071000 |2 bisacsh | |
| 084 | |a WD 5450 |q SEPA |2 rvk |0 (DE-625)rvk/148207: | ||
| 245 | 1 | 0 | |a Bile Acids and Their Receptors |c edited by Stefano Fiorucci, Eleonora Distrutti |
| 250 | |a 1st ed. 2019 | ||
| 264 | 1 | |a Cham |b Springer |c 2019 | |
| 300 | |a 1 Online-Ressource (X, 378 p. 57 illus., 37 illus. in color) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Handbook of Experimental Pharmacology |v 256 | |
| 490 | 0 | |a Springer eBook Collection | |
| 490 | 0 | |a Springer eBooks |a Biomedical and Life Sciences | |
| 520 | |a Preface -- Part 1. Bile acids as signaling molecules and their receptors -- 1. A short history of bile acid pharmacology -- 2. Bile acids activated receptors: a review of GPBAR1 (TGR5) and other G-protein-coupled receptors -- 3. Bile acid activated receptors: a review of FXR and other Nuclear receptors -- 4. The intestinal enterokine fibroblast growth factor 15/19 in bile acid metabolism -- 5. Signaling from intestine to the host. How bile acids regulate intestinal and liver immunity -- Part 2. General pharmacology of bile acid activated receptors and their ligands -- 6. Modeling of bile acid activated receptors as a tool for pharmacological development -- 7. Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists and antagonists -- 8. Non steroidal FXR ligands: current status and clinical applications -- 9. Intestinal selective FXR agonists and their potential in treating liver and metabolic diseases -- Part 3. Bile acids and their derivatives as drugs -- 10. UDCA, Nor-UDCA and T-UDCA: a review of their mechanisms of action and clinical applications -- 11. Chenodeoxycholic acid: an update on its therapeutic appplications and safety profile -- 12. Obeticholic acid: a review of its mechanisms of action and clinical applications -- Part 4. Bile acid activated receptors as therapeutic targets -- 13. Targeting FXR in cholestasis -- 14. FXR agonists for the treatment of NASH and other metabolic disorders -- 15. Targeting bile acids activated receptors in bariatric surgery | ||
| 520 | |a This book focusses on the latest results related to the field of bile acids as signaling molecules and describes how these receptors have become a major pharmacological target. It covers all major areas of research in this field, from genetics, chemistry, in silico modeling, molecular biology to clinical applications, offering a cross-country view of the functional role of bile acids as signaling molecules, virtually acting on all major areas of metabolism. While FXR and GPBAR1 are essential bile acid sensors that integrate the de novo bile acid synthesis with intestinal microbiota and liver metabolism, in a broader sense, BARs play a pathogenic role in the development of common human alignments including liver, intestinal and metabolic disorders, such as steatosis (NAFLD) and steato-hepatitis (NASH), diabetes, obesity and atherosclerosis | ||
| 650 | 0 | |a Toxicology | |
| 650 | 0 | |a Clinical medicine | |
| 650 | 0 | |a Pharmacology/Toxicology | |
| 650 | 0 | |a Gastroenterology | |
| 650 | 0 | |a Endocrinology | |
| 650 | 0 | |a Hepatology. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 2 | |a Bile Acids and Salts |x metabolism | |
| 650 | 2 | |a Receptors, Cytoplasmic and Nuclear |x chemistry | |
| 650 | 2 | |a Receptors, G-Protein-Coupled |x chemistry | |
| 650 | 2 | |a Signal Transduction | |
| 650 | 2 | |a Drug Delivery Systems | |
| 700 | 1 | |a Fiorucci, Stefano |e herausgeberin |4 edt | |
| 700 | 1 | |a Distrutti, Eleonora |e herausgeberin |4 edt | |
| 776 | 1 | |z 9783030220044 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Handbook of experimental pharmacology ; volume 256: Bile acids and their receptors |d Cham, Switzerland : Springer, 2019 |h x, 378 Seiten |w (DE-627)1679987089 |z 9783030220044 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-030-22005-1 |m X:SPRINGER |x Resolving-System |z lizenzpflichtig |
| 912 | |a ZDB-2-SBL |b 2019 | ||
| 912 | |a ZDB-2-SEB | ||
| 912 | |a ZDB-2-SXB |b 2019 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a ISIL_DE-28 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a ISIL_DE-3 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a ISIL_DE-Ma9 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a ISIL_DE-Ma14 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a ISIL_DE-715 | ||
| 912 | |a GBV_ILN_130 | ||
| 912 | |a ISIL_DE-700 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a ISIL_DE-517 | ||
| 912 | |a GBV_ILN_381 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a ISIL_DE-21 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a ISIL_DE-14 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a ISIL_DE-90 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a ISIL_DE-93 | ||
| 912 | |a GBV_ILN_2017 | ||
| 912 | |a ISIL_DE-576 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a ISIL_DE-953 | ||
| 936 | r | v | |a WD 5450 |b Steroide Sterine, Gallensäuren |k Biologie |k Biophysik, Biochemie, Physiologische Chemie |k Spezielle Biochemie und Biophysik |k Biochemie und Biophysik organischer Verbindungen |k Steroide Sterine, Gallensäuren |0 (DE-627)1271607972 |0 (DE-625)rvk/148207: |0 (DE-576)201607972 |
| 951 | |a BO | ||
| 953 | |2 045F |a 615 | ||
| 980 | |2 22 |1 01 |x 0018 |b 352514122X |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |h h64 Springer Biomedical |k Campuslizenz Universität Hamburg. - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y zi06404 |z 19-10-19 | ||
| 980 | |2 62 |1 01 |x 0028 |b 3563468729 |h ACQ |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y z |z 11-12-19 | ||
| 980 | |2 65 |1 01 |x 0003 |b 3525299427 |c 03 |f --%%-- |d ebook |e --%%-- |j --%%-- |h OLR-SEB-ZDB-2-SBL |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Die Weitergabe an Dritte sowie systematisches Downloaden sind untersagt. |y k3o |z 19-10-19 | ||
| 980 | |2 100 |1 01 |x 3100 |b 3525220715 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |c 09 |f --%%-- |d eBook Springer |e --%%-- |j --%%-- |h OLR-SEB |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y z |z 19-10-19 | ||
| 980 | |2 101 |1 01 |x 3101 |b 3525239106 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |c 09 |f --%%-- |d eBook Springer |e --%%-- |j --%%-- |h OLR-SEB |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y z |z 19-10-19 | ||
| 980 | |2 120 |1 01 |x 0715 |b 3525252978 |h OLR-ESP |k Campusweiter Zugriff (Universität Oldenburg). - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden. |y z |z 19-10-19 | ||
| 980 | |2 120 |1 02 |x 0715 |b 3580983199 |c 00 |f --%%-- |d --%%-- |e g |j --%%-- |h alma |y z |z 23-01-20 | ||
| 980 | |2 130 |1 01 |x 0700 |b 3525268092 |h OLR-SEB |k Vervielfältigungen (z. B. Kopien, Downloads) nur für den eigenen wissenschaftlichen Gebrauch. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots |y z |z 19-10-19 | ||
| 980 | |2 285 |1 01 |x 0517 |b 3589305908 |c 00 |f --%%-- |d --%%-- |e s |j --%%-- |h OLR-ESP-SBL |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y z |z 07-02-20 | ||
| 980 | |2 381 |1 01 |x 4381 |b 3525083475 |h OLR-SEB |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots |y z |z 19-10-19 | ||
| 980 | |2 2001 |1 01 |x DE-21 |b 3938542292 |c 00 |f --%%-- |d --%%-- |e --%%-- |j kp |y l01 |z 15-06-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3521429091 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Universitätslizenz |y l01 |z 10-10-19 | ||
| 980 | |2 2006 |1 01 |x DE-14 |b 3521345505 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 10-10-19 | ||
| 980 | |2 2014 |1 01 |x DE-90 |b 3521345513 |c 00 |f --%%-- |d --%%-- |e --%%-- |j kp |y l01 |z 10-10-19 | ||
| 980 | |2 2014 |1 02 |x DE-90 |b 3521345521 |c 00 |f --%%-- |d --%%-- |e --%%-- |j kp |y l02 |z 10-10-19 | ||
| 980 | |2 2015 |1 01 |x DE-93 |b 352134553X |c 00 |f --%%-- |d --%%-- |e p |j --%%-- |k Campuslizenz |y l01 |z 10-10-19 | ||
| 980 | |2 2017 |1 01 |x DE-576 |b 3521345548 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Besitznachweis BSZ nur für Dateneinspielung, keine echte Lizenz vorhanden |y l01 |z 10-10-19 | ||
| 980 | |2 2064 |1 01 |x DE-953 |b 3521429105 |c 00 |f --%%-- |d eBook Springer |e --%%-- |j n |k Elektronischer Volltext - Campuslizenz |y l01 |z 10-10-19 | ||
| 981 | |2 22 |1 01 |x 0018 |y Volltextzugang |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 22 |1 01 |x 0018 |y Nur für Angehörige der Universität Hamburg: Volltextzugang von außerhalb des Campus |r http://emedien.sub.uni-hamburg.de/han/SpringerEbooksUKE/doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 62 |1 01 |x 0028 |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 65 |1 01 |x 0003 |y Volltextzugang Campus |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 100 |1 01 |x 3100 |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 100 |1 01 |x 3100 |y für Uniangehörige: Zugang weltweit |r https://han.med.uni-magdeburg.de/han/SPR-eBook-BiomedicalandLifeScience-einzeln/doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 101 |1 01 |x 3101 |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 101 |1 01 |x 3101 |y für Uniangehörige: Zugang weltweit |r https://han.med.uni-magdeburg.de/han/SPR-eBook-BiomedicalandLifeScience-einzeln/doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 120 |1 01 |x 0715 |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 120 |1 02 |x 0715 |r http://49gbv-uob-primo.hosted.exlibrisgroup.com/openurl/49GBV_UOB/UOB_services_page?u.ignore_date_coverage=true&rft.mms_id=991014958738103501 | ||
| 981 | |2 130 |1 01 |x 0700 |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 285 |1 01 |x 0517 |y E-books (Springer) |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 381 |1 01 |x 4381 |y Zugriff nur für GEOMAR-Mitarbeiter / Access for GEOMAR employees only |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 2001 |1 01 |x DE-21 |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.redi-bw.de/start/unifr/EBooks-springer/10.1007/978-3-030-22005-1 | ||
| 981 | |2 2006 |1 01 |x DE-14 |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 2014 |1 01 |x DE-90 |y Zugang im Netz des KIT |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 2014 |1 02 |x DE-90 |y Zugang im Netz der HKA |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 2015 |1 01 |x DE-93 |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 981 | |2 2064 |1 01 |x DE-953 |r https://doi.org/10.1007/978-3-030-22005-1 | ||
| 982 | |2 2001 |1 01 |x DE-21 |8 00 |s s |a eBook-Springer-EBS-Biomedical-and-Life-Sciences-2018-2021-Auswahl | ||
| 983 | |2 120 |1 00 |x DE-715 |8 99 |a ww | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 120 |1 01 |x 0715 |a YH 1694 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 Springer Biomedical | ||
| 995 | |2 62 |1 01 |x 0028 |a ACQ | ||
| 995 | |2 62 |1 01 |x 0028 |a Springer-EBS | ||
| 995 | |2 65 |1 01 |x 0003 |a OLR-SEB-ZDB-2-SBL | ||
| 995 | |2 100 |1 01 |x 3100 |a OLR-SEB | ||
| 995 | |2 101 |1 01 |x 3101 |a OLR-SEB | ||
| 995 | |2 120 |1 01 |x 0715 |a OLR-ESP | ||
| 995 | |2 120 |1 02 |x 0715 |a alma | ||
| 995 | |2 130 |1 01 |x 0700 |a OLR-SEB | ||
| 995 | |2 285 |1 01 |x 0517 |a OLR-ESP-SBL | ||
| 995 | |2 381 |1 01 |x 4381 |a OLR-SEB | ||
| 998 | |2 2003 |1 01 |x DE-25 |0 10-10-19 |f 17 | ||